Compare Moderna, Inc. (MRNA) vs Tapestry, Inc. (TPR) Price & Performance

Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.

Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.

TPR trades at $142.16, up 0.49% today, with a neutral technical signal but strong fundamental momentum after three consecutive quarterly earnings beats. The stock carries high valuation ratios, including a P/E of 43.02, but demonstrates robust profitability with a 76.18% gross margin and 55.74% ROE. Recent corporate news includes the appointment of Jonathan Saunders as Kate Spade's Executive Creative Director, signaling brand revitalization efforts.

Outlook remains positive with a consensus price target of $183.88, implying 29% upside, supported by 75.6% analyst buy ratings. Key risks include elevated debt levels and margin compression from 2024's 12.23% to 2025's 2.61% net income margin. Investors should weigh strong brand positioning against valuation sensitivity and cyclical retail exposure.